32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

• Abdul Rafeh Naqash,
• Mahvish Muzaffar,
• Shravanti Macherla,
• Alessio Cortellini,
• James Clark,
• Emma Mi,
• Sanna Livanainen,
• Daria Gramenitskaya,
• Kevin O’Brien,
• Jussi Koivunen,
• Sweta Jonnalagadda,
• Shanker Polsani,
• Rahim Jiwani,
• Nitika Sharma,
• Chipman Stroud,
• Paul Walker,
• David Pinato

Affiliations

Abdul Rafeh Naqash

Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA

Mahvish Muzaffar

Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA

Shravanti Macherla

Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA

Alessio Cortellini

Aff1 Medical OncologySt. Salvatore Hospital L’Aquila Italy

James Clark

Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK

Emma Mi

3Imperial College London, London, UK

Sanna Livanainen

4University of Oulu, MRC Oulu, Oulu, Finland

Daria Gramenitskaya

3Imperial College London, London, UK

Kevin O’Brien

5East Carolina University, Greenville, NC, USA

Jussi Koivunen

4University of Oulu, MRC Oulu, Oulu, Finland

Sweta Jonnalagadda

5East Carolina University, Greenville, NC, USA

Shanker Polsani

5East Carolina University, Greenville, NC, USA

Rahim Jiwani

5East Carolina University, Greenville, NC, USA

Nitika Sharma

5East Carolina University, Greenville, NC, USA

Chipman Stroud

6Genentech, San-Francisco, CA, USA

Paul Walker

7Circulogene, Birmingham, AL, USA

David Pinato

3Imperial College London, London, UK